54.3 F
San Diego
Thursday, Mar 28, 2024
-Advertisement-

Diabetes Drug Heads for Market

San Diego-based Amylin Pharmaceuticals Inc. and its pharmaceutical partner, Eli Lilly & Co., announced April 29 that the Food and Drug Administration approved its diabetes drug exenatide for treating Type 2 diabetics.

The drug, which will be sold under the brand name Byetta, was approved as a combination therapy for treating Type 2 diabetics who are unsuccessful at controlling their blood sugar levels, the firms said.

In addition, the FDA informed the companies that Byetta could be approved as a stand-alone therapy for Type 2 diabetics, the firms said.

Any additional data that the drug makers submit to federal regulators is expected to receive a six-month review.

Byetta will be made available to pharmacies by June 1, the companies said.

Shares of Amylin fell 6.49 percent to $17 in morning trading April 29.

Marion Webb

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-